BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. - Wikidata - wikimedia - TriplyDB

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

http://www.wikidata.org/entity/Q37665135

about

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.Familial cancer among consecutive uterine cancer patients in Sweden.Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.Uterine carcinosarcoma/malignant mixed Müllerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy.Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing Actionable, pathogenic incidental findings in 1,000 participants' exomes.The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience.Genetics of endometrial cancer.Hereditary breast cancer syndromes and genetic testing.Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century.Aggregate penetrance of genomic variants for actionable disorders in European and African Americans.Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.Is there an association between type II endometrial carcinomas and breast cancers? A critical appraisal.Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes.Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy.[Pitfalls in the histopathological diagnostics of endometrial carcinoma and its precursors : Clinically relevant differential diagnoses, avoidance of false positive diagnoses].

P2860

Q21129302-F4EC1AC2-427C-4A09-8173-7DFE590852F4 Q26744525-CF32DB81-207F-4234-A611-EC61A6DAF1B7 Q28085485-6B961B0F-388F-470F-90E0-8EFEB84417FA Q28542563-8749A862-44F4-43DD-B272-F53891B83FD3 Q30234614-890315C2-60B1-4F27-8B92-B34B1B15B2E9 Q30370475-539ED825-0BE1-41DB-8F36-6D4120B1514F Q30413346-C5A049F5-A4A5-4704-9B64-AE846B69382C Q33646157-281BEFED-47B8-47A0-8735-866BA4CDC22C Q35519808-F5703CA5-4930-42A4-B154-F81A767C3B40 Q35736188-4057E4D3-A7BA-4501-B276-93F0AD6D3D09 Q36205570-037C8573-E6BF-4AF9-81FC-0D03CA8D5307 Q37097416-28A70B4D-A472-477F-A385-69592AEA20B4 Q37176931-1D0ECA32-1FDF-490B-90FB-5D152FB45CF3 Q37217044-04397D82-90B3-4DC3-A478-A1E15944BFFE Q38151415-281C37AF-FAB3-4BAF-9E86-7E27526AFDF0 Q38212634-B984B11F-43A6-4EFC-A3EB-B278D744938D Q38266306-C4E88BD2-655A-424D-A101-B65C95813334 Q38732720-086AE2CA-EE8A-42CC-A981-9F579430BECF Q39037647-CCEB79C0-A9D0-4FF7-883F-CDF4D4A228F9 Q39199102-8E7DC2E8-73E4-4F8B-B3D0-D29429EBC48E Q39639274-5634FB48-29A9-4041-9589-8743D2AF4D2A Q42619703-2032E4DD-6866-42C1-99E3-A7C16455D61B Q43858994-A97B317D-3CD1-42E6-B668-79A6259069BB Q47180579-D9F0BDA4-76B0-4D26-88FE-FC1B66B38B8B Q47735640-D6EC8177-4336-40B6-B327-509A93FD9958 Q52981800-A37C3E0D-0C36-4C91-B911-87F9A01012AF

P2860

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

http://www.wikidata.org/entity/Q37665135

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 July 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

@en

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

@nl

type

label

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

@en

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

@nl

prefLabel

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

@en

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

@nl

P1433

Q37665135-9058CE7B-7128-4861-B22A-3FFD9B7C2733

P1476

Q37665135-4866C191-0BD7-4D20-ADA4-6A0AD3F33C07

P2093

Q37665135-16235B90-F958-4031-ABF4-36E462C79D19

Q37665135-2AFEF1D5-F108-4DA3-9896-A5A0B91834FC

Q37665135-3BEE410D-66B8-4357-B62E-970D7698A68B

Q37665135-449C4E28-F468-495E-B735-915E9F44CBC6

Q37665135-4A5D0558-01FF-4DEB-83A9-CE8470063A55

Q37665135-A8F5ABEA-F24B-46E1-9FDE-9F45B2B5B33D

Q37665135-B17141A8-24C1-41E4-9B88-9894254F1FC3

Q37665135-BF8A4DEE-2402-4CD9-B629-993F9BF0F5D7

Q37665135-C0E36D57-34F7-47B3-AA44-083DE1FE0EA5

Q37665135-D8989C78-D1BE-43F1-8B19-48E3B6FEF4A0

P2860

Q37665135-1101FF28-3D04-4641-A69C-03416C48803A

Q37665135-172A8349-BC48-40AF-8315-8E7D279D8D5F

Q37665135-280728F4-7DAF-441E-A0C8-3A088CACD726

Q37665135-3C92AE46-E075-42E6-9F83-62FD469AC61D

Q37665135-4367FF65-4CD8-4A91-B765-44EC8C7B0F35

Q37665135-5678A3E9-23B6-46AC-81AC-10ADDA6D4125

Q37665135-5FED18EC-C566-403F-BF4C-EC872189149B

Q37665135-6392B26B-2F8D-4065-9C1A-7A0F7CC86027

Q37665135-6D6CFEEF-89D2-4A2A-8465-6053C7A7F0F2

Q37665135-7C2F74BA-64C7-4AB6-B041-954F3CA81285

P304

Q37665135-5C18D6DF-8B1B-4226-8938-94CCB7C8FC54

P31

Q37665135-E369A2C4-0966-4DCC-8602-5A46E0E90008

P356

Q37665135-2C8F62AF-9BD8-46D3-B469-A4D92858E3DD

P407

Q37665135-4255A603-6719-4E66-BFD2-D89D8A9DAEF2

P433

Q37665135-81203FE7-6547-4E46-8B1E-4B3555FA63DB

P478

Q37665135-66AB798C-E229-458A-8A23-1BBB9FB8AE53

P50

Q37665135-6111967F-995C-4B70-86AB-B4001624A754

Q37665135-FA436E11-E0E9-4B9A-AA54-0F9B9BCFFDE7

P577

Q37665135-33C6521B-0331-4C96-BDA0-A620256C7EB6

P5875

Q37665135-99607E7C-952A-416B-9F3E-79FCF8A7F9E2

P698

Q37665135-4EC90863-B18D-4F7E-B9FC-1F3D0B32355C

P932

Q37665135-BEF7D828-6905-4763-8B87-ADC4AAAAC1EF

P356

P1433

P1476

BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

@en

P2093

Akiva P Novetsky

http://www.w3.org/2001/XMLSchema#string

Anne Thornton

http://www.w3.org/2001/XMLSchema#string

Christopher Pennil

http://www.w3.org/2001/XMLSchema#string

David Mutch

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Swisher

http://www.w3.org/2001/XMLSchema#string

Kathryn P Pennington

http://www.w3.org/2001/XMLSchema#string

Kathy J Agnew

http://www.w3.org/2001/XMLSchema#string

Ming Lee

http://www.w3.org/2001/XMLSchema#string

Paul Goodfellow

http://www.w3.org/2001/XMLSchema#string

Rochelle Garcia

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

Germline mutations in RAD51D confer susceptibility to ovarian cancer

Mutations in BRIP1 confer high risk of ovarian cancer

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

Endometrial cancer and Lynch syndrome: clinical and pathologic considerations

Uterine serous carcinoma: increased familial risk for lynch-associated malignancies

Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations.

Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.

Accurate and exact CNV identification from targeted high-throughput sequence data.

P304

332-338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.27720

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Mary-Claire King

P577

2012-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229323381

http://www.w3.org/2001/XMLSchema#string

P698

22811390

http://www.w3.org/2001/XMLSchema#string

P932

3966566

http://www.w3.org/2001/XMLSchema#string